{"component": "clause", "props": {"groups": [{"samples": [{"hash": "3O2mWVYwjGs", "uri": "/contracts/3O2mWVYwjGs#global-development-plan", "label": "Option for a License Agreement", "score": 31.3408622742, "published": true}, {"hash": "as5YRln7rA4", "uri": "/contracts/as5YRln7rA4#global-development-plan", "label": "Option for a License Agreement (Macrogenics Inc)", "score": 24.7563304901, "published": true}, {"hash": "gwnFq6CKuKM", "uri": "/contracts/gwnFq6CKuKM#global-development-plan", "label": "Option for a License Agreement (Macrogenics Inc)", "score": 24.6741962433, "published": true}], "size": 6, "snippet_links": [{"key": "license-term", "type": "clause", "offset": [11, 23]}, {"key": "licensed-program", "type": "definition", "offset": [33, 49]}, {"key": "development-of-licensed-products", "type": "clause", "offset": [55, 87]}, {"key": "this-agreement", "type": "clause", "offset": [94, 108]}, {"key": "pursuant-to-a", "type": "definition", "offset": [156, 169]}, {"key": "research-and-development-plan", "type": "definition", "offset": [203, 232]}, {"key": "detailed-budget", "type": "clause", "offset": [292, 307]}, {"key": "manufacturing-process-development-costs", "type": "definition", "offset": [338, 377]}, {"key": "development-budget", "type": "clause", "offset": [388, 406]}, {"key": "resource-allocations", "type": "clause", "offset": [438, 458]}, {"key": "the-parties", "type": "clause", "offset": [463, 474]}, {"key": "general-principle", "type": "clause", "offset": [490, 507]}, {"key": "the-allocation", "type": "clause", "offset": [513, 527]}, {"key": "license-grant-date", "type": "definition", "offset": [680, 698]}, {"key": "initial-draft", "type": "definition", "offset": [726, 739]}, {"key": "the-global", "type": "clause", "offset": [743, 753]}, {"key": "approval-by", "type": "clause", "offset": [775, 786]}, {"key": "each-global", "type": "definition", "offset": [822, 833]}, {"key": "specific-activities", "type": "definition", "offset": [876, 895]}, {"key": "clinical-studies", "type": "definition", "offset": [924, 940]}, {"key": "by-each-party", "type": "clause", "offset": [957, 970]}, {"key": "estimated-timeline", "type": "clause", "offset": [980, 998]}, {"key": "for-development", "type": "clause", "offset": [999, 1014]}, {"key": "in-order-to", "type": "clause", "offset": [1073, 1084]}, {"key": "the-data", "type": "clause", "offset": [1092, 1100]}, {"key": "by-both-parties", "type": "clause", "offset": [1141, 1156]}, {"key": "obtain-regulatory-approvals", "type": "clause", "offset": [1161, 1188]}, {"key": "the-united-states", "type": "definition", "offset": [1222, 1239]}, {"key": "the-eu", "type": "clause", "offset": [1245, 1251]}, {"key": "the-sponsor", "type": "clause", "offset": [1270, 1281]}, {"key": "servier-territory", "type": "definition", "offset": [1323, 1340]}, {"key": "responsible-for", "type": "clause", "offset": [1361, 1376]}, {"key": "development-activities", "type": "definition", "offset": [1377, 1399]}, {"key": "obtaining-regulatory-approval", "type": "clause", "offset": [1408, 1437]}, {"key": "macrogenics-territory", "type": "definition", "offset": [1564, 1585]}], "snippet": "During the License Term for each Licensed Program, the Development of Licensed Products under this Agreement under such Licensed Program shall be conducted pursuant to a reasonably comprehensive written research and development plan (each, a \u201cGlobal Development Plan\u201d), which shall include a detailed budget for all Development Costs and Manufacturing Process Development Costs (each, a \u201cDevelopment Budget\u201d), and which shall include the resource allocations for the Parties based upon the general principle that the allocation shall endeavor to take advantage of the respective resources, capabilities and expertise of MacroGenics and Servier, respectively. Within *** after the License Grant Date, the JRDC shall prepare an initial draft of the Global Development Plan for approval by the JSC for such Licensed Program. Each Global Development Plan also shall set forth the specific activities (including non-clinical and clinical studies to be conducted by each Party) and the estimated timeline for Development of Licensed Products licensed under such Licensed Program in order to obtain the data that the Parties intend will be useful, by both Parties, to obtain Regulatory Approvals of the Licensed Products in both the United States, and the EU. Servier shall be the sponsor of all clinical studies conducted in the Servier Territory and shall be solely responsible for Development activities and for obtaining Regulatory Approval for Licensed Products in the Servier Territory, and MacroGenics shall be the sponsor of all clinical studies conducted in the MacroGenics Territory and shall be solely responsible for Development activities and for obtaining Regulatory Approval for Licensed Products in the MacroGenics Territory. The JRDC shall discuss which Party(ies) shall be the sponsor of all clinical studies conducted in countries of both the MacroGenics Territory and the Servier Territory under such Licensed Program.", "hash": "b0b46bcfef0e788134021e5401d72e09", "id": 1}, {"samples": [{"hash": "cY0AWAWUjNB", "uri": "/contracts/cY0AWAWUjNB#global-development-plan", "label": "License, Development and Commercialization Agreement (Nanobiotix S.A.)", "score": 33.2655715942, "published": true}, {"hash": "qH40gYWW6A", "uri": "/contracts/qH40gYWW6A#global-development-plan", "label": "License, Development and Commercialization Agreement (Nanobiotix S.A.)", "score": 32.6851463318, "published": true}, {"hash": "2Dlhg6YAjRL", "uri": "/contracts/2Dlhg6YAjRL#global-development-plan", "label": "License, Development and Commercialization Agreement (LianBio)", "score": 32.4880218506, "published": true}], "size": 4, "snippet_links": [{"key": "development-of-the-licensed-product", "type": "clause", "offset": [20, 55]}, {"key": "outside-of-the-territory", "type": "clause", "offset": [56, 80]}, {"key": "pursuant-to-a", "type": "definition", "offset": [99, 112]}, {"key": "written-plan", "type": "definition", "offset": [113, 125]}, {"key": "prior-to-the", "type": "clause", "offset": [159, 171]}, {"key": "phase-iii-trial", "type": "definition", "offset": [178, 193]}, {"key": "provide-the", "type": "clause", "offset": [236, 247]}, {"key": "initial-global-development-plan", "type": "clause", "offset": [248, 279]}, {"key": "in-the-territory", "type": "clause", "offset": [366, 382]}, {"key": "the-global", "type": "clause", "offset": [394, 404]}, {"key": "development-activities", "type": "definition", "offset": [459, 481]}, {"key": "the-world", "type": "definition", "offset": [534, 543]}, {"key": "from-time-to-time", "type": "clause", "offset": [559, 576]}, {"key": "current-global-development-plan", "type": "definition", "offset": [621, 652]}, {"key": "licensed-products", "type": "clause", "offset": [661, 678]}], "snippet": "Nanobiotix\u2019s global Development of the Licensed Product outside of the Territory will be conducted pursuant to a written plan (the \u201cGlobal Development Plan\u201d). Prior to the first Phase III Trial for any Licensed Product, Nanobiotix will provide the initial Global Development Plan to the JSC for its review, discussion, and [***] regarding activities to be conducted in the Territory, approval. The Global Development Plan will include an outline of all major Development activities for the Licensed Product to be conducted throughout the world by Nanobiotix. From time to time, Nanobiotix may propose updates to the then-current Global Development Plan for the Licensed Products, to the JSC to review and discuss and [***] regarding activities to be conducted in the Territory, approval.", "hash": "3b039b6f4f0c23c6e7079c359771c6ac", "id": 2}, {"samples": [{"hash": "550s9kYTeLb", "uri": "/contracts/550s9kYTeLb#global-development-plan", "label": "Strategic Collaboration, Option and License Agreement (CRISPR Therapeutics AG)", "score": 27.7652301788, "published": true}, {"hash": "jdr0xImj5BW", "uri": "/contracts/jdr0xImj5BW#global-development-plan", "label": "Strategic Collaboration, Option and License Agreement (CRISPR Therapeutics AG)", "score": 27.516084671, "published": true}, {"hash": "2fcTrAnDc6t", "uri": "/contracts/2fcTrAnDc6t#global-development-plan", "label": "Strategic Collaboration, Option and License Agreement (Vertex Pharmaceuticals Inc / Ma)", "score": 27.1245727539, "published": true}], "size": 4, "snippet_links": [{"key": "the-jdc", "type": "clause", "offset": [0, 7]}, {"key": "the-development", "type": "clause", "offset": [21, 36]}, {"key": "shared-products", "type": "definition", "offset": [40, 55]}, {"key": "by-the-parties", "type": "clause", "offset": [56, 70]}, {"key": "in-the-field", "type": "clause", "offset": [71, 83]}, {"key": "in-the-territory", "type": "clause", "offset": [84, 100]}, {"key": "in-accordance-with", "type": "definition", "offset": [140, 158]}, {"key": "the-global", "type": "clause", "offset": [218, 228]}, {"key": "the-shared", "type": "clause", "offset": [289, 299]}, {"key": "regulatory-approval", "type": "clause", "offset": [333, 352]}, {"key": "regulatory-strategy", "type": "definition", "offset": [366, 385]}, {"key": "design-criteria", "type": "definition", "offset": [404, 419]}, {"key": "allocation-of-responsibilities", "type": "clause", "offset": [424, 454]}, {"key": "between-the-parties", "type": "clause", "offset": [455, 474]}, {"key": "development-budget", "type": "clause", "offset": [564, 582]}, {"key": "as-needed", "type": "clause", "offset": [660, 669]}, {"key": "for-approval", "type": "definition", "offset": [696, 708]}, {"key": "the-parties-will", "type": "clause", "offset": [710, 726]}, {"key": "activities-under", "type": "clause", "offset": [799, 815]}, {"key": "the-project-team", "type": "clause", "offset": [845, 861]}, {"key": "an-experienced", "type": "clause", "offset": [877, 891]}, {"key": "team-leader", "type": "definition", "offset": [892, 903]}, {"key": "composition-of-the", "type": "clause", "offset": [932, 950]}, {"key": "the-project-leader", "type": "clause", "offset": [986, 1004]}, {"key": "based-on", "type": "clause", "offset": [1005, 1013]}, {"key": "available-personnel", "type": "clause", "offset": [1014, 1033]}, {"key": "each-party", "type": "definition", "offset": [1039, 1049]}, {"key": "its-responsibilities", "type": "clause", "offset": [1098, 1118]}, {"key": "in-good-faith", "type": "clause", "offset": [1153, 1166]}, {"key": "reasonable-care-and-diligence", "type": "definition", "offset": [1176, 1205]}, {"key": "provide-the", "type": "clause", "offset": [1229, 1240]}, {"key": "periodic-updates", "type": "clause", "offset": [1250, 1266]}, {"key": "of-activities", "type": "clause", "offset": [1290, 1303]}, {"key": "pursuant-to-the", "type": "definition", "offset": [1304, 1319]}], "snippet": "The JDC will oversee the Development of Shared Products by the Parties in the Field in the Territory. Each Shared Product will be Developed in accordance with a global development plan (the \u201cGlobal Development Plan\u201d). The Global Development Plan will include a plan for the Development of the Shared Product in the Territory through Regulatory Approval, including a regulatory strategy, high-level study design criteria, an allocation of responsibilities between the Parties, timelines and a budget for activities conducted under the Global Development Plan (the \u201cDevelopment Budget\u201d). The JDC will update the Global Development Plan [***] (or more frequently as needed) and submit it to the JSC for approval. The Parties will establish a project team (the \u201cProject Team\u201d) to oversee and coordinate activities under the Global Development Plan. The Project Team be formed with an experienced team leader (\u201cProject Leader\u201d), and the composition of the Project Team will be determined by the Project Leader based on available personnel from each Party across functions. The Project Team will conduct its responsibilities under the Global Development Plan in good faith and with reasonable care and diligence. The Project Team will provide the JDC with periodic updates regarding the progress of activities pursuant to the Global Development Plan.", "hash": "0b9bd245370fbe9978ccce50259aa875", "id": 3}, {"samples": [{"hash": "5FakLyB0nmv", "uri": "/contracts/5FakLyB0nmv#global-development-plan", "label": "Collaboration Agreement (Surface Oncology, Inc.)", "score": 29.2217655182, "published": true}, {"hash": "a77nconioih", "uri": "/contracts/a77nconioih#global-development-plan", "label": "Collaboration Agreement (Surface Oncology, Inc.)", "score": 29.1724853516, "published": true}, {"hash": "6quj7ED1kuV", "uri": "/contracts/6quj7ED1kuV#global-development-plan", "label": "Collaboration Agreement (Surface Oncology, Inc.)", "score": 28.8767967224, "published": true}], "size": 3, "snippet_links": [{"key": "development-activities", "type": "definition", "offset": [47, 69]}, {"key": "the-applicable", "type": "clause", "offset": [120, 134]}, {"key": "global-licensed-products", "type": "clause", "offset": [165, 189]}, {"key": "initial-regulatory-approval", "type": "definition", "offset": [201, 228]}, {"key": "by-novartis", "type": "clause", "offset": [266, 277]}, {"key": "commercially-reasonable-efforts", "type": "definition", "offset": [284, 315]}, {"key": "major-market-countries", "type": "clause", "offset": [323, 345]}, {"key": "the-design", "type": "clause", "offset": [357, 367]}, {"key": "this-exhibit", "type": "definition", "offset": [404, 416]}, {"key": "replaced-with", "type": "clause", "offset": [434, 447]}, {"key": "the-secretary", "type": "clause", "offset": [523, 536]}, {"key": "the-securities-and-exchange-commission", "type": "clause", "offset": [540, 578]}, {"key": "confidential-treatment", "type": "definition", "offset": [617, 639]}, {"key": "pursuant-to-rule", "type": "clause", "offset": [640, 656]}, {"key": "securities-act-of-1933", "type": "definition", "offset": [683, 705]}, {"key": "as-amended", "type": "definition", "offset": [707, 717]}, {"key": "phase-1-study", "type": "definition", "offset": [731, 744]}, {"key": "work-plan", "type": "definition", "offset": [798, 807]}, {"key": "time-table", "type": "clause", "offset": [812, 822]}, {"key": "initial-global-development-plan", "type": "clause", "offset": [864, 895]}, {"key": "each-global", "type": "definition", "offset": [900, 911]}, {"key": "the-option", "type": "clause", "offset": [939, 949]}, {"key": "section-422", "type": "clause", "offset": [1023, 1036]}, {"key": "terms-of", "type": "clause", "offset": [1042, 1050]}, {"key": "and-development", "type": "clause", "offset": [1052, 1067]}, {"key": "at-all-times", "type": "definition", "offset": [1127, 1139]}, {"key": "compliance-with-all-applicable-laws", "type": "clause", "offset": [1161, 1196]}, {"key": "in-accordance-with", "type": "definition", "offset": [1201, 1219]}, {"key": "professional-and-ethical-standards", "type": "clause", "offset": [1220, 1254]}, {"key": "the-global", "type": "clause", "offset": [1318, 1328]}, {"key": "will-provide", "type": "clause", "offset": [1421, 1433]}, {"key": "the-jdc", "type": "clause", "offset": [1474, 1481]}], "snippet": "On a Global Target-by-Global Target basis, the Development activities that are necessary or useful to be undertaken for the applicable Global Antibody Candidates or Global Licensed Products to achieve initial Regulatory Approval for each of the Indications selected by Novartis using Commercially Reasonable Efforts in the Major Market Countries (including the design of CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH \u201c[***]\u201d. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. the initial Phase 1 Study) will be set forth in reasonable detail in a written work plan and time table (each, a \u201cGlobal Development Plan\u201d). The initial Global Development Plan for each Global Target will be included in the Option IND Package for such Global Target provided by Surface to Novartis under Section 4.2.2. The terms of, and Development activities set forth in, each Global Development Plan will at all times be designed to be in compliance with all applicable Laws and in accordance with professional and ethical standards customary in the pharmaceutical industry. Novartis will update the Global Development Plan for such Global Antibody Candidates and Global Licensed Products [***] and will provide such updated Global Development Plan to the JDC.", "hash": "f117c3cc886b0507904d603b846e3f80", "id": 4}, {"samples": [{"hash": "9C7alHk3aS3", "uri": "/contracts/9C7alHk3aS3#global-development-plan", "label": "License and Collaboration Agreement (Zai Lab LTD)", "score": 30.6399726868, "published": true}, {"hash": "84Vg8qhn8s2", "uri": "/contracts/84Vg8qhn8s2#global-development-plan", "label": "License and Collaboration Agreement (Zai Lab LTD)", "score": 30.4811763763, "published": true}, {"hash": "kMHNAgtRpI1", "uri": "/contracts/kMHNAgtRpI1#global-development-plan", "label": "License and Collaboration Agreement (NovoCure LTD)", "score": 29.8131408691, "published": true}], "size": 3, "snippet_links": [{"key": "development-of-licensed-products", "type": "clause", "offset": [18, 50]}, {"key": "pursuant-to-a", "type": "definition", "offset": [69, 82]}, {"key": "as-amended", "type": "definition", "offset": [109, 119]}, {"key": "from-time-to-time", "type": "clause", "offset": [120, 137]}, {"key": "in-accordance-with", "type": "definition", "offset": [138, 156]}, {"key": "section-53", "type": "clause", "offset": [162, 173]}, {"key": "the-parties-agree", "type": "clause", "offset": [213, 230]}, {"key": "tt-fields", "type": "definition", "offset": [249, 258]}, {"key": "clinical-studies", "type": "definition", "offset": [274, 290]}, {"key": "cancer-indication", "type": "definition", "offset": [340, 357]}, {"key": "ovarian-cancer", "type": "definition", "offset": [371, 385]}, {"key": "the-parties-shall", "type": "clause", "offset": [450, 467]}, {"key": "initial-global-development-plan", "type": "clause", "offset": [495, 526]}, {"key": "following-the-effective-date", "type": "clause", "offset": [545, 573]}, {"key": "in-addition-to", "type": "clause", "offset": [575, 589]}, {"key": "activities-under", "type": "clause", "offset": [608, 624]}, {"key": "territory-development-plan", "type": "definition", "offset": [629, 655]}, {"key": "the-global", "type": "clause", "offset": [698, 708]}, {"key": "global-clinical-trials", "type": "clause", "offset": [770, 792]}, {"key": "other-development-activities", "type": "clause", "offset": [892, 920]}, {"key": "commercially-reasonable-efforts", "type": "definition", "offset": [1164, 1195]}, {"key": "amendments-to-the", "type": "clause", "offset": [1248, 1265]}, {"key": "current-global-development-plan", "type": "definition", "offset": [1271, 1302]}, {"key": "to-the-extent", "type": "clause", "offset": [1304, 1317]}, {"key": "relate-to", "type": "definition", "offset": [1360, 1369]}, {"key": "proposed-amendments", "type": "definition", "offset": [1408, 1427]}, {"key": "for-review", "type": "clause", "offset": [1439, 1449]}], "snippet": "(a) NVCR\u2019s global Development of Licensed Products will be conducted pursuant to a written development plan (as amended from time to time in accordance with this Section 5.3, the \u201cGlobal Development Plan\u201d), which the Parties agree shall include (i) TT Fields Multi-Regional Clinical Studies for (1) the NSCLC Indication, (2) the pancreatic cancer Indication, and (3) the ovarian cancer Indication, for each of which, Zai [***]; and (ii) a [***].\n(b) The Parties shall discuss and agree upon the initial Global Development Plan within [***] days following the Effective Date. In addition to Zai\u2019s Development activities under the Territory Development Plan, Zai shall [***] Global Development Plan. The Global Development Plan shall include (i) an outline only of NVCR\u2019s global Clinical Trials for Licensed Products, (ii) details and timelines of the [***], (iii) details and timelines of any other Development activities [***], and (iv) [***] Global Development Plan [***], which for each of the TT Fields Multi-Regional Clinical Studies for the NSCLC Indication, the pancreatic cancer Indication and the ovarian cancer Indication, shall be up to [***], using its Commercially Reasonable Efforts.\n(c) From time to time, NVCR may make and implement amendments to the then-current Global Development Plan. To the extent such amendments are (x) material, and (y) relate to the Territory, NVCR shall submit such proposed amendments to the JSC for review and discussion before adopting such amendments.", "hash": "86f2878fcf6c33993f80e3355564219a", "id": 5}, {"samples": [{"hash": "aVKGeFwMkzu", "uri": "/contracts/aVKGeFwMkzu#global-development-plan", "label": "Joint Development and Commercialization Agreement", "score": 31.3408622742, "published": true}, {"hash": "2faKVNpxked", "uri": "/contracts/2faKVNpxked#global-development-plan", "label": "Joint Development and Commercialization Agreement (CRISPR Therapeutics AG)", "score": 28.9616699219, "published": true}], "size": 3, "snippet_links": [{"key": "the-jdc", "type": "clause", "offset": [0, 7]}, {"key": "shared-products", "type": "definition", "offset": [44, 59]}, {"key": "the-research", "type": "clause", "offset": [64, 76]}, {"key": "by-the-parties", "type": "clause", "offset": [99, 113]}, {"key": "in-the-field", "type": "clause", "offset": [114, 126]}, {"key": "in-the-territory", "type": "clause", "offset": [127, 143]}, {"key": "in-accordance-with", "type": "definition", "offset": [183, 201]}, {"key": "prepared-by", "type": "definition", "offset": [337, 348]}, {"key": "the-project-team", "type": "clause", "offset": [349, 365]}, {"key": "after-the-effective-date", "type": "clause", "offset": [384, 408]}, {"key": "approved-by", "type": "definition", "offset": [422, 433]}, {"key": "agreed-by", "type": "clause", "offset": [471, 480]}, {"key": "in-writing", "type": "definition", "offset": [493, 503]}, {"key": "the-global", "type": "clause", "offset": [505, 515]}, {"key": "at-all-times", "type": "definition", "offset": [538, 550]}, {"key": "regulatory-approval", "type": "clause", "offset": [634, 653]}, {"key": "regulatory-strategy", "type": "definition", "offset": [667, 686]}, {"key": "design-criteria", "type": "definition", "offset": [705, 720]}, {"key": "allocation-of-responsibilities", "type": "clause", "offset": [725, 755]}, {"key": "between-the-parties", "type": "clause", "offset": [756, 775]}, {"key": "initial-development-budget", "type": "definition", "offset": [910, 936]}, {"key": "this-agreement", "type": "clause", "offset": [977, 991]}, {"key": "each-party-will", "type": "clause", "offset": [993, 1008]}, {"key": "program-expenses", "type": "definition", "offset": [1015, 1031]}, {"key": "plans-and-budgets", "type": "definition", "offset": [1078, 1095]}, {"key": "article-7", "type": "definition", "offset": [1188, 1197]}, {"key": "as-needed", "type": "clause", "offset": [1234, 1243]}, {"key": "for-review", "type": "clause", "offset": [1366, 1376]}, {"key": "certain-confidential-information", "type": "clause", "offset": [1565, 1597]}, {"key": "contained-in", "type": "definition", "offset": [1598, 1610]}, {"key": "omitted-and-filed-separately-with-the-securities-and-exchange-commission", "type": "clause", "offset": [1655, 1727]}, {"key": "pursuant-to-rule", "type": "clause", "offset": [1728, 1744]}, {"key": "securities-exchange-act-of-1934", "type": "clause", "offset": [1758, 1789]}, {"key": "as-amended", "type": "definition", "offset": [1791, 1801]}, {"key": "table-of-contents", "type": "definition", "offset": [1803, 1820]}], "snippet": "The JDC will oversee the Development of the Shared Products and the Research of Follow-On Products by the Parties in the Field in the Territory. The Shared Products will be Developed in accordance with a global development plan (the \u201cGlobal Development Plan\u201d), which will include the Development Budget (as defined below), which will be prepared by the Project Team within [***] days after the Effective Date and shall be approved by the JDC thereafter. Unless otherwise agreed by the Parties in writing, the Global Development Plan will at all times include a plan for the Development of the Shared Products in the Territory through Regulatory Approval, including a regulatory strategy, high-level study design criteria, an allocation of responsibilities between the Parties, timelines and a budget for activities conducted under the Global Development Plan (the \u201cDevelopment Budget\u201d). Until such time as the initial Development Budget has been established in accordance with this Agreement, each Party will incur Program Expenses in a manner substantially consistent with the plans and budgets previously discussed by the Parties and such Program Expenses will be shared as provided in ARTICLE 7. On [***] basis (or more frequently as needed), the Project Team will update the Global Development Plan and will submit the updated Global Development Plan to the JDC for review and discussion. The JDC will review and discuss the updated Global Development Plan and submit such updated Global Development Plan to the JSC for review, discussion and approval. [***] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. Table of Contents", "hash": "25958bd9157596a101e072bd87903dcc", "id": 6}, {"samples": [{"hash": "ja9C75GK32L", "uri": "/contracts/ja9C75GK32L#global-development-plan", "label": "Collaboration and License Agreement (Macrogenics Inc)", "score": 26.1663246155, "published": true}], "size": 3, "snippet_links": [{"key": "with-respect-to", "type": "clause", "offset": [7, 22]}, {"key": "as-specified", "type": "clause", "offset": [28, 40]}, {"key": "use-commercially-reasonable-efforts", "type": "clause", "offset": [62, 97]}, {"key": "development-of-the-products", "type": "clause", "offset": [113, 140]}, {"key": "the-territory", "type": "clause", "offset": [145, 158]}, {"key": "in-accordance-with", "type": "definition", "offset": [159, 177]}, {"key": "the-global", "type": "clause", "offset": [178, 188]}, {"key": "subject-to", "type": "definition", "offset": [227, 237]}, {"key": "sharing-of-expenses", "type": "clause", "offset": [251, 270]}, {"key": "the-co", "type": "clause", "offset": [292, 298]}, {"key": "funding-option", "type": "clause", "offset": [299, 313]}, {"key": "right-to-make", "type": "clause", "offset": [339, 352]}, {"key": "amendments-to-the", "type": "clause", "offset": [353, 370]}, {"key": "with-company", "type": "clause", "offset": [422, 434]}, {"key": "development-obligations", "type": "clause", "offset": [437, 460]}, {"key": "development-activities", "type": "definition", "offset": [558, 580]}, {"key": "regulatory-approval", "type": "clause", "offset": [618, 637]}, {"key": "for-products", "type": "clause", "offset": [638, 650]}, {"key": "plans-and", "type": "clause", "offset": [723, 732]}, {"key": "regulatory-materials", "type": "definition", "offset": [771, 791]}, {"key": "provided-that", "type": "definition", "offset": [916, 929]}, {"key": "no-obligation-to", "type": "clause", "offset": [949, 965]}, {"key": "delivery-of-the", "type": "clause", "offset": [1059, 1074]}, {"key": "option-deadline", "type": "definition", "offset": [1134, 1149]}, {"key": "funding-termination-date", "type": "definition", "offset": [1218, 1242]}, {"key": "global-development-costs", "type": "definition", "offset": [1396, 1420]}, {"key": "current-global-development-plan", "type": "definition", "offset": [1507, 1538]}, {"key": "review-to", "type": "clause", "offset": [1591, 1600]}, {"key": "approval-of", "type": "definition", "offset": [1666, 1677]}, {"key": "in-good-faith", "type": "clause", "offset": [1802, 1815]}, {"key": "company-will", "type": "clause", "offset": [1817, 1829]}, {"key": "clinical-trials", "type": "clause", "offset": [1882, 1897]}, {"key": "initial-product", "type": "definition", "offset": [1908, 1923]}, {"key": "to-the-extent", "type": "clause", "offset": [1931, 1944]}, {"key": "the-parties-acknowledge-and-agree-that", "type": "clause", "offset": [2086, 2124]}, {"key": "ability-to", "type": "definition", "offset": [2135, 2145]}, {"key": "conduct-of", "type": "clause", "offset": [2284, 2294]}], "snippet": "Except with respect to [***]as specified below, Company shall use Commercially Reasonable Efforts to conduct the Development of the Products for the Territory in accordance with the Global Development Plan, at its own expense (subject to MacroGenics\u2019 sharing of expenses upon its exercise of the Co-Funding Option). Company shall have the right to make amendments to the Global Development Plan, which shall be consistent with Company\u2019s Development obligations set forth in Section 4.2(a), and each amended Global Development Plan shall include all material Development activities anticipated to be required to obtain Regulatory Approval for Products in [***], as well as timelines regarding such activities, including the plans and timelines for preparing the necessary Regulatory Materials. The Global Development Plan shall include any Development activities with respect to [***] that Company elects to conduct, provided that Company shall have no obligation to conduct Development or to seek Regulatory Approval for Products in [***]. Beginning with the delivery of the Co-Funding Materials and continuing through the Co-Funding Option Deadline (if MacroGenics does not exercise the Co-Funding Option) and the Co-Funding Termination Date (if MacroGenics exercises the Co-Funding Option), Company shall update the Global Development Plan to include a then-current, non-binding budget for any Global Development Costs. During the Co-Funding Term, Company shall update and amend, as appropriate, the then-current Global Development Plan and shall submit such updates and/or amendments for review to the JSC. While the Global Development Plan shall not require the approval of the JSC, Company shall review and consider all comments to the Global Development Plan received from MacroGenics at the JSC in good faith. Company will consider including, in the Global Development Plan, Clinical Trials using the Initial Product [***], to the extent that Company reasonably determines that such Clinical Trials are feasible from a medical, scientific, regulatory and commercial perspective. The Parties acknowledge and agree that Company\u2019s ability to conduct such Clinical Trials may be subject to [***] and that Company shall have no obligation to conduct such Clinical Trials unless the conduct of such Clinical Trials is [***].", "hash": "6e0ccc516e6876ac483efcc01bd57ec4", "id": 7}, {"samples": [{"hash": "bDAHimqEeF9", "uri": "/contracts/bDAHimqEeF9#global-development-plan", "label": "License and Collaboration Agreement (Zai Lab LTD)", "score": 29.3258037567, "published": true}, {"hash": "3N1KWrUy2rB", "uri": "/contracts/3N1KWrUy2rB#global-development-plan", "label": "License and Collaboration Agreement (Five Prime Therapeutics Inc)", "score": 29.1560573578, "published": true}], "size": 2, "snippet_links": [{"key": "five-prime", "type": "definition", "offset": [0, 10]}, {"key": "development-of-licensed-products", "type": "clause", "offset": [20, 52]}, {"key": "pursuant-to-a", "type": "definition", "offset": [71, 84]}, {"key": "as-amended", "type": "definition", "offset": [111, 121]}, {"key": "from-time-to-time", "type": "clause", "offset": [122, 139]}, {"key": "in-accordance-with", "type": "definition", "offset": [140, 158]}, {"key": "section-53", "type": "clause", "offset": [164, 175]}, {"key": "the-parties-shall", "type": "clause", "offset": [209, 226]}, {"key": "initial-global-development-plan", "type": "clause", "offset": [254, 285]}, {"key": "following-the-effective-date", "type": "clause", "offset": [299, 327]}, {"key": "in-addition-to", "type": "clause", "offset": [329, 343]}, {"key": "activities-under", "type": "clause", "offset": [362, 378]}, {"key": "territory-development-plan", "type": "definition", "offset": [383, 409]}, {"key": "the-global", "type": "clause", "offset": [429, 439]}, {"key": "in-the-territory", "type": "clause", "offset": [518, 534]}, {"key": "major-development", "type": "definition", "offset": [667, 684]}, {"key": "clinical-trials", "type": "clause", "offset": [711, 726]}, {"key": "the-development", "type": "clause", "offset": [795, 810]}, {"key": "other-development-activities", "type": "clause", "offset": [923, 951]}, {"key": "development-of-the-licensed-product", "type": "clause", "offset": [1031, 1066]}, {"key": "by-zai", "type": "clause", "offset": [1104, 1110]}, {"key": "the-allocation", "type": "clause", "offset": [1112, 1126]}, {"key": "responsibility-for", "type": "clause", "offset": [1137, 1155]}, {"key": "with-respect-to", "type": "clause", "offset": [1285, 1300]}, {"key": "allocated-to", "type": "definition", "offset": [1372, 1384]}, {"key": "subject-to", "type": "definition", "offset": [1455, 1465]}, {"key": "further-discussion", "type": "clause", "offset": [1466, 1484]}, {"key": "between-the-parties", "type": "clause", "offset": [1485, 1504]}, {"key": "amendments-to-the", "type": "clause", "offset": [1559, 1576]}, {"key": "current-global-development-plan", "type": "definition", "offset": [1582, 1613]}, {"key": "to-the-extent", "type": "clause", "offset": [1615, 1628]}, {"key": "relate-to", "type": "definition", "offset": [1671, 1680]}, {"key": "proposed-amendments", "type": "definition", "offset": [1725, 1744]}, {"key": "for-review", "type": "clause", "offset": [1756, 1766]}], "snippet": "Five Prime\u2019s global Development of Licensed Products will be conducted pursuant to a written development plan (as amended from time to time in accordance with this Section 5.3, the \u201cGlobal Development Plan\u201d). The Parties shall discuss and agree upon the initial Global Development Plan within [***] following the Effective Date. In addition to Zai\u2019s Development activities under the Territory Development Plan, Zai shall support the global Development of Licensed Products by conducting certain Development activities in the Territory in accordance with and as set forth in the Global Development Plan. The Global Development Plan shall include (i) an outline of all major Development activities (including all Clinical Trials) for Licensed Products by Five Prime, (ii) details and timelines of the Development activities in the Territory assigned to Zai to support the FPA144-004 Study, (iii) details and timelines of any other Development activities (including Clinical Trials) in the Territory assigned to Zai to support global Development of the Licensed Product, and (iv) unless otherwise agreed to by Zai, the allocation to Zai of responsibility for any Development activities included within the initial Global Development Plan that are to be conducted in the Territory, except with respect to Taiwan, which Development activities for the FPA144-004 Study shall be allocated to Five Prime, and which other Development activities in Taiwan shall be subject to further discussion between the Parties. From time to time, Five Prime may make and implement amendments to the then-current Global Development Plan. To the extent such amendments are (x) material, and (y) relate to the Territory, Five Prime shall submit such proposed amendments to the JSC for review and discussion before adopting such amendments.", "hash": "5c40f404cc617628a8ff6137a6079eb9", "id": 8}, {"samples": [{"hash": "jX6wVHjWkL4", "uri": "/contracts/jX6wVHjWkL4#global-development-plan", "label": "License and Collaboration Agreement (Cytokinetics Inc)", "score": 28.0527038574, "published": true}, {"hash": "eXRR7Up9KMr", "uri": "/contracts/eXRR7Up9KMr#global-development-plan", "label": "License and Collaboration Agreement (Cytokinetics Inc)", "score": 27.8391513824, "published": true}], "size": 2, "snippet_links": [{"key": "development-activities", "type": "definition", "offset": [43, 65]}, {"key": "during-the-option-period", "type": "clause", "offset": [66, 90]}, {"key": "in-accordance-with", "type": "definition", "offset": [91, 109]}, {"key": "decision-making", "type": "definition", "offset": [208, 223]}, {"key": "the-global", "type": "clause", "offset": [235, 245]}, {"key": "amendment-execution-date", "type": "definition", "offset": [282, 306]}, {"key": "this-amendment", "type": "clause", "offset": [322, 336]}, {"key": "prepared-by", "type": "definition", "offset": [482, 493]}, {"key": "delivery-of-the", "type": "clause", "offset": [537, 552]}, {"key": "data-package", "type": "definition", "offset": [559, 571]}, {"key": "if-applicable", "type": "clause", "offset": [595, 608]}, {"key": "certain-confidential-information", "type": "clause", "offset": [629, 661]}, {"key": "contained-in", "type": "definition", "offset": [662, 674]}, {"key": "omitted-and-filed-separately-with-the-securities-and-exchange-commission", "type": "clause", "offset": [719, 791]}, {"key": "pursuant-to-rule", "type": "clause", "offset": [792, 808]}, {"key": "securities-exchange-act-of-1934", "type": "clause", "offset": [822, 853]}, {"key": "as-amended", "type": "definition", "offset": [855, 865]}], "snippet": "Cytokinetics will conduct the Cytokinetics Development Activities during the Option Period in accordance with a global development plan (the \u201cGlobal Development Plan\u201d), for which Cytokinetics will have final decision making authority. The Global Development Plan existing as of the Amendment Execution Date is attached to this Amendment as Exhibit D. Cytokinetics shall prepare an updated Global Development Plan and shall provide Astellas with such updated Global Development Plan prepared by Cytokinetics concurrent with Cytokinetics\u2019 delivery of the Early Data Package and Late Data Package (if applicable) to Astellas. [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.", "hash": "dcba29871ee6c264f47a07cab945f307", "id": 9}, {"samples": [{"hash": "hZSIas0irqI", "uri": "/contracts/hZSIas0irqI#global-development-plan", "label": "Co Development and License Agreement (Ambrx Biopharma Inc.)", "score": 32.4031486511, "published": true}, {"hash": "gTQltiTN0CU", "uri": "/contracts/gTQltiTN0CU#global-development-plan", "label": "Co Development and License Agreement (Ambrx Biopharma Inc.)", "score": 32.2005462646, "published": true}], "size": 2, "snippet_links": [{"key": "after-the-effective-date", "type": "clause", "offset": [40, 64]}, {"key": "joint-steering-committee", "type": "clause", "offset": [98, 122]}], "snippet": "To be adopted by the JSC within 60 days after the Effective Date.\nExhibit 3.1: Initial Members of Joint Steering Committee", "hash": "ece10f283888fc9362daba298260869c", "id": 10}], "next_curs": "CmASWmoVc35sYXdpbnNpZGVyY29udHJhY3RzcjwLEhZDbGF1c2VTbmlwcGV0R3JvdXBfdjU2IiBnbG9iYWwtZGV2ZWxvcG1lbnQtcGxhbiMwMDAwMDAwYQyiAQJlbhgAIAA=", "clause": {"children": [["general", "General"], ["lead-party", "Lead party"], ["amendments", "Amendments"], ["diagnostic-products-and-biomarkers", "Diagnostic Products and Biomarkers"], ["non-cancer-indications", "Non-Cancer Indications"]], "size": 98, "parents": [["development", "Development"], ["development-plans", "Development Plans"], ["development-program", "Development Program"], ["definitions", "DEFINITIONS"], ["miscellaneous", "Miscellaneous"]], "title": "Global Development Plan", "id": "global-development-plan", "related": [["development-plan", "Development Plan", "Development Plan"], ["professional-development-plan", "Professional Development Plan", "Professional Development Plan"], ["commercialization-plan", "Commercialization Plan", "Commercialization Plan"], ["development-plans", "Development Plans", "Development Plans"], ["professional-development-program", "Professional Development Program", "Professional Development Program"]], "related_snippets": [], "updated": "2026-03-20T05:48:33+00:00"}, "json": true, "cursor": ""}}